These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22414609)

  • 1. Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.
    Dijkstra JR; Opdam FJ; Boonyaratanakornkit J; Schönbrunner ER; Shahbazian M; Edsjö A; Hoefler G; Jung A; Kotsinas A; Gorgoulis VG; López-Ríos F; de Stricker K; Rouleau E; Biesmans B; van Krieken JH
    J Mol Diagn; 2012; 14(3):187-91. PubMed ID: 22414609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applicability of a System for fully automated nucleic acid extraction from formalin-fixed paraffin-embedded sections for routine KRAS mutation testing.
    Lehmann A; Schewe C; Hennig G; Denkert C; Weichert W; Budczies J; Dietel M
    Diagn Mol Pathol; 2012 Jun; 21(2):114-9. PubMed ID: 22555094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
    Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
    J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
    Okayama N; Nishioka M; Hazama S; Sakai K; Suehiro Y; Maekawa M; Sakamoto J; Iwamoto S; Kato T; Mishima H; Oka M; Hinoda Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):165-71. PubMed ID: 20926413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
    Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
    J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.
    Ogasawara N; Bando H; Kawamoto Y; Yoshino T; Tsuchihara K; Ohtsu A; Esumi H
    Jpn J Clin Oncol; 2011 Jan; 41(1):52-6. PubMed ID: 20696815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.
    Kwon MJ; Lee SE; Kang SY; Choi YL
    Pathol Res Pract; 2011 Dec; 207(12):762-8. PubMed ID: 22070922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
    Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
    BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.
    Normanno N; Pinto C; Castiglione F; Fenizia F; Barberis M; Marchetti A; Fontanini G; De Rosa G; Taddei GL
    J Transl Med; 2015 Sep; 13():287. PubMed ID: 26335936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.
    De Miglio MR; Mura A; Uras MG; Manca A; Contini M; Murgia L; Zinellu A; Sotgia S; Carru C; Massarelli G; Cossu-Rocca P
    Diagn Mol Pathol; 2010 Dec; 19(4):201-8. PubMed ID: 21052001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Setting future standards for KRAS testing in colorectal cancer.
    van Krieken H; Tol J
    Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
    [No Abstract]   [Full Text] [Related]  

  • 14. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues.
    Dufort S; Richard MJ; de Fraipont F
    Anal Biochem; 2009 Aug; 391(2):166-8. PubMed ID: 19464247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparability study of 5 commercial KRAS tests.
    Oliner K; Juan T; Suggs S; Wolf M; Sarosi I; Freeman DJ; Gyuris T; Baron W; Bakker A; Parker A; Patterson SD
    Diagn Pathol; 2010 Apr; 5():23. PubMed ID: 20398393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
    Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
    Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis.
    van Eijk R; Stevens L; Morreau H; van Wezel T
    Exp Mol Pathol; 2013 Feb; 94(1):121-5. PubMed ID: 22750048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.
    Tembuyser L; Ligtenberg MJ; Normanno N; Delen S; van Krieken JH; Dequeker EM
    J Mol Diagn; 2014 May; 16(3):371-7. PubMed ID: 24631467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS testing in clinical laboratory: optimizing targeted therapy.
    Miravalle L; Lefferts JA; Al-Haddad M; Tsongalis GJ; Cheng L
    Cancer Genomics Proteomics; 2012; 9(5):337-41. PubMed ID: 22990113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma.
    Kamel-Reid S; Zhang T; Persons DL; Nikiforova MN; Halling KC;
    Arch Pathol Lab Med; 2012 Jan; 136(1):26-32. PubMed ID: 22208484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.